<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trientine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trientine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Trientine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11435" href="/d/html/11435.html" rel="external">see "Trientine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="121956" href="/d/html/121956.html" rel="external">see "Trientine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F230917"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Clovique [DSC];</li>
<li>Cuvrior;</li>
<li>Syprine</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55349274"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>MAR-Trientine;</li>
<li>Waymade-Trientine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F230930"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Chelating Agent</li></ul></div>
<div class="block doa drugH1Div" id="F230920"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="356294e9-9c29-43ce-b91c-44f10819a66f">Wilson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilson disease (alternative agent):</b>
<b>Note:</b> Trientine hydrochloride capsules (Clovique and generics, Syprine) are not substitutable on a mg-per-mg basis with trientine tetrahydrochloride tablets (Cuvrior) due to differences in bioavailability and amount of trientine base in each formulation (AASLD [Schilsky 2022]; Mohr 2023; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Trientine hydrochloride capsules (Clovique and generics, Syprine): Oral: </b>Initial: 750 to 1,250 mg/day <b>or </b>15 to 20 mg/kg/day in 2 to 4 divided doses (AASLD [Schilsky 2022]; manufacturer's labeling). Increase dose over a 2- to 3-week period based on clinical response up to a maximum of 2 <b>g</b>/day; usual maintenance dose: 10 to 15 mg/kg/day in 2 to 3 divided doses (AASLD [Schilsky 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Trientine tetrahydrochloride tablets (Cuvrior):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Initial dosage (patients switching from penicillamine)</i>: Oral:</b> Discontinue penicillamine and initiate trientine tetrahydrochloride at 300 to 3,000 mg/day in 2 equally divided doses based on penicillamine total daily dose according to the table below.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Dose Conversion from Penicillamine to Trientine Tetrahydrochloride Tablets (Cuvrior)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Current penicillamine total daily dosage</p></th>
<th align="left">
<p style="text-indent:0em;">Initial trientine tetrahydrochloride (Cuvrior) total daily dosage<sup>a</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>a</sup> Total daily dose should be divided equally into 2 doses; if the number of tablets cannot be equally divided between doses, then administer the higher dose in the morning and the lower dose in the evening.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">125 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">300 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">250 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">600 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">375 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">900 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">500 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">900 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">625 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">1,200 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">750 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">1,500 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">875 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">1,800 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">1,000 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">2,100 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">1,125 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">2,400 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">1,375 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">2,700 mg/day</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥1,500 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">3,000 mg/day</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Dosage titration: </i></b>Adjust total daily dose based on clinical response up to a maximum of 3 <b>g</b>/day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990096"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987382"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F230921"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Use with caution; initiate at lower end of the dosing range.</p></div>
<div class="block dop drugH1Div" id="F230926"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="121956" href="/d/html/121956.html" rel="external">see "Trientine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Trientine is available in 2 formulations; the trientine hydrochloride capsule (Clovique and generics, Syprine) and trientine tetrahydrochloride tablet (Cuvrior) are not bioequivalent due to differences in amount of trientine base delivered per dose and bioavailability (AASLD [Schilsky 2022]; Mohr 2023; manufacturer's labeling). Dosing is product specific; use caution; the tetrahydrochloride tablets (Cuvrior) are only approved in adults.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="356294e9-9c29-43ce-b91c-44f10819a66f">Wilson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilson disease:</b> Children and Adolescents: Trientine hydrochloride capsules (Clovique and generics, Syprine): Oral: Initial: 20 mg/kg/day (round dose to the nearest 250 mg) in 2 to 3 divided doses; maximum <i>initial</i> daily dose: 1,000 mg/<b>day</b>; titrate dose based on clinical response and free serum copper (non-ceruloplasmin bound copper) concentrations and/or 24-hour urinary copper excretion; usual maintenance dose: 10 to 15 mg/kg/day or 900 to 1,500 mg/day in 2 to 3 divided doses (AASLD [Schilsky 2022]; EASL 2012; ESPGHAN [Socha 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum daily dose:</p>
<p style="text-indent:-2em;margin-left:6em;">Children: 1,500 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: 2,000 mg/<b>day</b>.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51193011"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193012"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F230901"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, change in bowel habits (including abnormal stools, constipation, and soft stools)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Emotional lability</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Iron deficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Fixed drug eruption (Roberts 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis (Boga 2015), gastritis (Roberts 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia (Roberts 2008), pancytopenia (Roberts 2008), sideroblastic anemia (reversible) (Roberts 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Myasthenia gravis, neurological deterioration (worsening) (European Association for the Study of the Liver 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dystonia, muscle spasm, rhabdomyolysis (Aslan 2019)</p></div>
<div class="block coi drugH1Div" id="F230911"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to trientine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F230899"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Copper deficiency: Induced by treatment; may lead to hepatic iron overload and/or sideroblastic anemia; reassess dose (AASLD [Schilsky 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, characterized by rash, have been reported with trientine tetrahydrochloride (Cuvrior). Hypersensitivity has not been reported with trientine hydrochloride (Clovique and generics, Syprine); however, industrial workers exposed to trientine for prolonged periods have reported asthma, bronchitis, and dermatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Iron deficiency: May cause iron-deficiency potentially resulting in anemia, especially in menstruating or pregnant females.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurologic worsening: May occur with treatment initiation; less common than with penicillamine (AASLD [Schilsky 2022]).</p></div>
<div class="block foc drugH1Div" id="F230907"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clovique: 250 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Syprine: 250 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tetrahydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cuvrior: 300 mg [scored]</p></div>
<div class="block geq drugH1Div" id="F230895"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F230913"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Syprine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $255.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Trientine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $229.43 - $242.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $460.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cuvrior Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $229.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55349275"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block adm drugH1Div" id="F230909"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer at least 1 hour before or 2 hours after meals and at least 1 hour apart from any drug, food, or milk. May be taken closer to meals if needed to improve adherence (AASLD [Schilsky 2022]; EASL 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Trientine hydrochloride capsules (Clovique and generics, Syprine):</i> Do not open or chew capsule; swallow whole with water; any skin exposed to the contents of a capsule should be promptly washed with water.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Trientine tetrahydrochloride tablets (Cuvrior):</i> Swallow whole; do not crush, chew, or dissolve tablets. Scored tablet may be divided into 2 equal halves.</p></div>
<div class="block admp drugH1Div" id="F52613969"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Trientine hydrochloride capsules (Clovique and generics, Syprine): Administer on an empty stomach at least 1 hour before or at least 2 hours after meals and at least 1 hour apart from any other drug, food, or milk; however, administration closer to meals may be considered if it improves adherence (AASLD [Schilsky 2022]; EASL 2012; manufacturer's labeling). Swallow capsule whole with water; do not chew or open capsule. Any skin exposed to the contents of a capsule should be promptly washed with water.</p></div>
<div class="block use drugH1Div" id="F230908"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilson disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Trientine hydrochloride capsules (Clovique and generics, Syprine): Treatment of patients with Wilson disease who are <b>intolerant</b> to penicillamine.</p>
<p style="text-indent:-2em;margin-left:6em;">Limitations of use: Not recommended in cystinuria or rheumatoid arthritis; not indicated for biliary cirrhosis.</p>
<p style="text-indent:-2em;margin-left:4em;">Trientine tetrahydrochloride tablets (Cuvrior): Treatment of adult patients with stable Wilson disease who are decoppered and <b>tolerant</b> to penicillamine.</p></div>
<div class="block mst drugH1Div" id="F230937"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Trientine may be confused with TRENtal®, tretinoin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300173"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F230903"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Trientine. Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F13851639"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food, dairy products, or other sources of polyvalent cations will be chelated by trientine. Management: Should be taken 1 hour before or 2 hours after meals and at least 1 hour apart from any drug, food, or milk. May be taken closer to meals if needed to improve adherence (AASLD [Schilsky 2022]; EASL 2012).</p></div>
<div class="block pri drugH1Div" id="F13823812"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Treatment of Wilson disease should be maintained during pregnancy; dose reduction (25% to 50% of prepregnancy dose) should be considered (AASLD [Schilsky 2022]).</p></div>
<div class="block brc drugH1Div" id="F17930566"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if trientine is present in breast milk. The manufacturer recommends that caution be exercised when administering trientine to breastfeeding patients.</p></div>
<div class="block dic drugH1Div" id="F230914"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Should be taken 1 hour before or 2 hours after meals and at least 1 hour apart from any drug, food, or milk.</p></div>
<div class="block mop drugH1Div" id="F5661288"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic 24-hour urinary copper assessment (every 6 to 12 months); serum non-ceruloplasmin bound copper (NCC) at baseline, 3 months after treatment initiation, and approximately every 6 months thereafter; liver biochemistries; CBC; tests of liver synthetic function (eg, INR); urinalysis (AASLD [Schilsky 2022]); fever and skin changes during the first month of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Treatment efficacy</i></b>
<b>
<i>: </i></b>Adequacy of the initial dose is monitored by the rate of urinary copper excretion; 24-hour urinary copper excretion may exceed 1,000 mcg per 24 hours at treatment initiation and decrease as copper stores are depleted (eg, ~150 to 500 mcg per 24 hours during maintenance therapy) (AASLD [Schilsky 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Lack of efficacy: </i></b>Nonadherence versus poor trientine absorption may need to be investigated if urinary copper excretion rises over time (eg &gt;500 mcg per 24 hours) in conjunction with a rise in serum copper and NCC (eg &gt;15 mcg/dL) despite appropriately titrated trientine dosage (AASLD [Schilsky 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Overtreatment:</i></b> Overtreatment may need to be investigated if urinary copper excretion is &lt;100 mcg per 24 hours and/or serum copper levels and NCC (eg &lt;5 mcg/dL) are lower than expected (AASLD [Schilsky 2022]).</p></div>
<div class="block pha drugH1Div" id="F230898"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Trientine is an oral chelating agent structurally dissimilar from penicillamine and other available chelating agents. Induces cupriuresis by chelating with copper to form stable, soluble complexes that are excreted in the urine; also chelates copper in the intestinal tract to decrease copper absorption.</p></div>
<div class="block phk drugH1Div" id="F5661284"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Poor (AASLD [Schilsky 2022]); trientine tetrahydrochloride is absorbed faster and to a greater extent than trientine hydrochloride (Weiss 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: To acetyltrien (chelating activity significantly less than parent) (AASLD [Schilsky 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Trientine hydrochloride (as Univar [international product]): Mean 23.2 hours (Weiss 2021); Trientine tetrahydrochloride: 13.8 to 16.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Trientine hydrochloride (as Univar [international product]): Median: 3 hours (range: 1.25 to 6.02 hours) (Weiss 2021); Trientine tetrahydrochloride: 1.25 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (1% as parent; 8% as metabolite) (AASLD [Schilsky 2022]).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F230915"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cufence</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Trientine Waymade</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Willentine</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Triogen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cubrital | Cuchel | Syprine</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cufence</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cufence</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cufence | Trientine tillomed</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cufence | Trientine dichlorhydrate | Triethylenetetramine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cufence | Trientine | Trientine dihydrochloride tillomed</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cufence | Trientine/univar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cufence</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cufence</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cuchel</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Metalite</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Metalite | Syprine | Trientab</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cufence | Trientine</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cufence</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Syprine | Trientine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cufence</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cufence | Syprine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Trientine Waymade</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Clovique | Syprine | Trientine HCL | Trientine hydrochloride</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cufence | Syprine | Trientina | Trientine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cufence | Trientine tillomed</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Syprine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cufence | Syprine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Novils | Sipryne | Wilentin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Metacu | Metalite | Syprine | Trientine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31749561">
<a name="31749561"></a>Aslan N, Yavuz S, Yildizdas D, et al. Trientine-induced rhabdomyolysis in an adolescent with Wilson's disease. <i>Indian J Crit Care Med</i>. 2019;23(10):489-490. doi:10.5005/jp-journals-10071-23271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/31749561/pubmed" id="31749561" target="_blank">31749561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26589720">
<a name="26589720"></a>Boga S, Jain D, Schilsky ML. Trientine induced colitis during therapy for Wilson disease: a case report and review of the literature. <i>BMC Pharmacol Toxicol</i>. 2015;16:30. doi:10.1186/s40360-015-0031-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/26589720/pubmed" id="26589720" target="_blank">26589720</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Clovique (trientine hydrochloride) [prescribing information]. Warrendale, PA: Kadmon Pharmaceuticals; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8435326">
<a name="8435326"></a>Condamine L, Hermine O, Alvin P, Levine M, Rey C, Courtecuisse V. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. <i>Br J Haematol</i>. 1993;83(1):166-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/8435326/pubmed" id="8435326" target="_blank">8435326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cuvrior.1">
<a name="Cuvrior.1"></a>Cuvrior (trientine tetrahydrochloride) [prescribing information]. Chicago, IL: Orphalan; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7583074">
<a name="7583074"></a>Dahlman T, Hartvig P, Löfholm M, Nordlinder H, Lööf L, Westermark K. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). <i>QJM</i>. 1995;88(9):609-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/7583074/pubmed" id="7583074" target="_blank">7583074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22340672">
<a name="22340672"></a>European Association for Study of Liver. EASL clinical practice guidelines: Wilson's disease. <i>J Hepatol</i>. 2012;56(3):671-685. doi:10.1016/j.jhep.2011.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/22340672/pubmed" id="22340672" target="_blank">22340672</a>]</span>
<span class="doi">10.1016/j.jhep.2011.11.007</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9284083">
<a name="9284083"></a>Kodama H, Murata Y, Iitsuka T, et al, “Metabolism of Administrated Triethylene Tetramine Dihydrochloride In Humans,” <i>Life Sci</i>, 1997, 61(9):899-907.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/9284083/pubmed" id="9284083" target="_blank">9284083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36331262">
<a name="36331262"></a>Mohr I, Bourhis H, Woimant F, et al. Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl. <i>J Gastroenterol Hepatol</i>. 2023;38(2):219-224. doi:10.1111/jgh.16050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/36331262/pubmed" id="36331262" target="_blank">36331262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8757970">
<a name="8757970"></a>Perry AR, Pagliuca A, Fitzsimons EJ, Mufti GJ, Williams R. Acquired sideroblastic anaemia induced by a copper-chelating agent. <i>Int J Hematol</i>. 1996;64(1):69-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/8757970/pubmed" id="8757970" target="_blank">8757970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18506894">
<a name="18506894"></a>Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. <i>Hepatology</i>. 2008;47(6):2089-2111. doi:10.1002/hep.22261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/18506894/pubmed" id="18506894" target="_blank">18506894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36152019">
<a name="36152019"></a>Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. Published online December 7, 2022. doi:10.1002/hep.32805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/36152019/pubmed" id="36152019" target="_blank">36152019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11479773">
<a name="11479773"></a>Shiono Y, Hayashi H, Wakusawa S, Yano M. Ultrastructural identification of iron and copper accumulation in the liver of a male patient with Wilson disease. <i>Med Electron Microsc</i>. 2001;34(1):54-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/11479773/pubmed" id="11479773" target="_blank">11479773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29341979">
<a name="29341979"></a>Socha P, Janczyk W, Dhawan A, et al. Wilson's Disease in Children: A Position Paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr.</i> 2018;66(2):334-344. doi: 10.1097/MPG.0000000000001787.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/29341979/pubmed" id="29341979" target="_blank">29341979</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Syprine (trientine hydrochloride) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; September 2020.</div>
</li>
<li>
<div class="reference">
                  Trientine hydrochloride capsules [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6121964">
<a name="6121964"></a>Walshe JM, “Treatment of Wilson's Disease With Trientine (Triethylene Tetramine) Dihydrochloride,” <i>Lancet</i>, 1982, 1(8273):643-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/6121964/pubmed" id="6121964" target="_blank">6121964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34357516">
<a name="34357516"></a>Weiss KH, Thompson C, Dogterom P, et al. Comparison of the pharmacokinetic profiles of trientine tetrahydrochloride and trientine dihydrochloride in healthy subjects. <i>Eur J Drug Metab Pharmacokinet</i>. 2021;46(5):665-675. doi:10.1007/s13318-021-00704-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trientine-drug-information/abstract-text/34357516/pubmed" id="34357516" target="_blank">34357516</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10019 Version 254.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
